American Century Companies Inc. lifted its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 6.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,450,707 shares of the company's stock after acquiring an additional 209,740 shares during the period. American Century Companies Inc. owned 2.13% of Alkermes worth $99,242,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently made changes to their positions in the company. Centiva Capital LP purchased a new stake in shares of Alkermes in the third quarter valued at approximately $367,000. Natixis Advisors LLC boosted its stake in Alkermes by 190.3% during the third quarter. Natixis Advisors LLC now owns 36,490 shares of the company's stock worth $1,021,000 after buying an additional 23,921 shares during the last quarter. Sanctuary Advisors LLC grew its holdings in Alkermes by 254.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company's stock valued at $944,000 after buying an additional 23,541 shares in the last quarter. BNP Paribas Financial Markets increased its stake in shares of Alkermes by 74.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company's stock worth $4,184,000 after acquiring an additional 63,939 shares during the last quarter. Finally, Barclays PLC raised its holdings in shares of Alkermes by 108.8% during the 3rd quarter. Barclays PLC now owns 423,931 shares of the company's stock worth $11,867,000 after acquiring an additional 220,893 shares during the period. 95.21% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Alkermes
In other news, EVP Craig C. Hopkinson sold 144,419 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total transaction of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 4.89% of the stock is owned by insiders.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on ALKS shares. Royal Bank of Canada started coverage on shares of Alkermes in a report on Thursday, March 13th. They issued a "sector perform" rating and a $40.00 price objective for the company. StockNews.com raised shares of Alkermes from a "buy" rating to a "strong-buy" rating in a research note on Thursday, February 13th. UBS Group upgraded Alkermes from a "sell" rating to a "neutral" rating and increased their price objective for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. The Goldman Sachs Group raised their target price on Alkermes from $30.00 to $32.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Finally, HC Wainwright reaffirmed a "neutral" rating and issued a $46.00 price target on shares of Alkermes in a research note on Thursday, February 13th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $39.38.
Read Our Latest Stock Analysis on ALKS
Alkermes Price Performance
Shares of NASDAQ ALKS traded down $0.32 during mid-day trading on Friday, hitting $33.21. The company had a trading volume of 922,403 shares, compared to its average volume of 1,751,921. The company has a market capitalization of $5.40 billion, a PE ratio of 15.30, a price-to-earnings-growth ratio of 2.20 and a beta of 0.62. The business's 50-day simple moving average is $33.38 and its 200 day simple moving average is $30.22. Alkermes plc has a 1-year low of $22.90 and a 1-year high of $36.45.
Alkermes (NASDAQ:ALKS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. On average, analysts expect that Alkermes plc will post 1.31 EPS for the current year.
Alkermes Profile
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Featured Stories
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
